Compugen (CGEN) Reiterated at Buy by Stifel After Overview of COM701 Trial
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).The analyst commented, "We’re reiterating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




